Economic Evaluation in Genomic and Precision Medicine

Christina Mitropoulou is Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine. Her research interests revolve around the health economic evaluation of genome-guided therapeutic interventions. Also, Christina Mitropoulou participates as Executive Committee member of the Ubiquitous Pharmacogenomics (U-PGx) project and coordinates the health economic evaluation of the PREPARE clinical study on pre-emptive Pharmacogenomics testing, involving approx. 8000 patients from 7 clinical sites and she is an active member of the Pharmacogenomics Access and Reimbursement Coalition. Christina Mitropoulou has published several original articles on this topic in leading scientific journals and has edited two textbooks on economic evaluation in Genomic Medicine that are published by Elsevier/Academic Press. Sarah Wordsworth is at the University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UK. James Buchanan PhD joined the Health Economics Research Centre in 2005 and works predominantly on projects examining the economics of translating genomic high-throughput technologies from research into clinical practice, especially in cancer and infectious disease. In 2011 he was awarded a National Institute for Health Research Doctoral Research Fellowship to undertake a PhD in Health Economics investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating a targeted array in haematological cancers. Previous genomics projects include an economic evaluation of the use of genetic testing to identify the somatic mutations that can cause common cancers, an economic evaluation of the use of genetic tests to identify gastrointestinal pathogens to improve hospital infection control practice, the development of an economic modelling framework to evaluate novel genomic diagnostic tools in inflammatory bowel disease, and a cost-effectiveness analysis of microarray technology in the UK National Health Service. His other interests include costing methodology and the valuation of patient preferences. He also teaches on a range of undergraduate and postgraduate courses at the University of Oxford, and teaches advanced cost-effectiveness analysis methods to health economists and policy makers. Dr. George Patrinos is an Associate Professor at the University of Patras School of Health Sciences (Department of Pharmacy) in Patras, Greece with Adjunct positions in Rotterdam, the Netherlands and Al-Ain, United Arab Emirates. His research interests span the fields of molecular diagnostics, high-throughput mutation screening, the development of online mutation diagnostic tools, and the implementation of genomics into healthcare, particularly for health systems in developing countries. George Patrinos has published more than 170 scientific papers in peer reviewed journals on topics related to genetics, genomic medicine, pharmacogenomics, molecular diagnostics, and social and economic evaluation for genomic medicine. Dr. Patrinos is also the co-author of Economic Evaluation in Genomic Medicine (2015) and co-Editor of Molecular Diagnostics, Second Edition (2009), both published by Elsevier, and serves as Communicating Editor for the journal Human Mutation. Additionally, he is co-organizer of the international meeting series “Golden Helix Symposia” and “Golden Helix Pharmacogenomics Days”.

• 1. Introduction to economic evaluation in health sciences2. Foundations of pharmacogenomics and personalized medicine 3. Economic evaluation of genome-guided treatment in oncology4. Economic evaluation of rare diseases and the diagnostic odyssey5. Economic analysis of pharmacogenetic testing for HLA-based adverse drug reactions6. Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing7. Theoretical models for economic evaluation in genomic and personalized medicine8. Using big data in economic evaluations in genomics: Challenges and opportunities9. Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting10. Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions